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Summary Global eradication of tuberculosis (TB) depends on identification and treatment of all active TB
cases and of the two billion people who are estimated to be latently infected with Mycobacterium
tuberculosis. The past decade has seen a renaissance of scientific activities and funder investment into
development of new TB drugs, diagnostics, biomarkers and vaccines. This viewpoint critically
summarises the promising portfolio of more accurate TB diagnostics, new TB drugs and vaccines
that have been endorsed by the STOP TB Partnership. Increasing numbers of Phase 2 and 3 drug, vaccine
and diagnostic clinical trials in high-TB endemic areas reflect substantial progress towards attaining
Global STOP-TB Partnership targets. Achievement of STOP-TB Partnership goals will crucially depend
on political will and serious investment by funders and developing country governments into improving
delivery of better health services and living conditions for their people. Long-term sustainability of any
newer tools implemented at point of care is essential.
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Introduction
Global eradication of tuberculosis (TB) ultimately depends
on identification and treatment of the all active TB cases
and of the two billion people who, according to WHO
estimates, are latently infected with Mycobacterium
tuberculosis (M. tuberculosis) (Zumla et al. 2011; Sudre
et al. 1992). The latter is seemingly impossible; thus,
current WHO focus is on the former. Improvement of
social factors driving the current TB pandemic (poverty,
poor housing, poor nutrition, chronic liver diseases,
smoking, diabetes, immunosuppression and poor health
services) is crucial in curtailing the epidemic. They will
need to be tackled in parallel with existing and newer
diagnostics, drugs and vaccines, if the current global
pandemic is to be controlled (Grange et al. 2001; Zumla &
Grange 2010). The progress made in these areas over the
past decade is critically reviewed here in the light of the
stated goals of the STOP TB Partnership.
Establishment of the STOP TB Partnership
In response to the global emergency of the TB pandemic,
the Stop TB Partnership was established by the World
Health Assembly (WHA) in May 2000; it comprises
>1200 donors, national and international organisations,
government and non-governmental organisations. The
Partnership consists of a Partners’ Forum, a Coordinating
Board and a Partnership Secretariat currently hosted by
WHO in Geneva, Switzerland (WHO, 2006). It has seven
working groups (WG); three are focussed on new tools
required to achieve TB control: TB diagnostics, drugs and
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vaccines. A critical aspect of TB control is early accurate
diagnosis and effective treatment of active TB disease to
render patients non-infectious. An effective vaccine to
prevent development of TB is an ideal, which has not
been realised. Testing of new TB vaccine candidates is
underway, and identification of clinically meaningful and
robust biomarkers to gauge vaccine take and efficacy
remains unavailable.
In 2006, the TB pandemic continued to kill 2 million
people annually and was growing by 1% each year, despite
WHO having declared it a ‘Global Emergency’ over a
decade earlier. The Global Plan to Stop TB (2006–2015)
(WHO, 2006) was launched in 2006 by the STOP TB
Partnership, and this formed the basis of a universally
accepted roadmap for substantially reducing the global
burden of TB by 2015. This was updated in the 2010
WHO Report. The Research and Development (R&D)
component of the Global Plan to Stop TB envisaged that
fundamental basic research will allow discovery of new TB
diagnostics, drugs and vaccines (Ma et al. 2010; Wallis
et al. 2010; Kaufmann et al. 2010). The aims of the Global
Plan to Stop TB, although ambitious, were clear, and a
huge financial investment was required to achieve its aims.
For new TB diagnostics, a portfolio of new and
improved diagnostic tests for the detection of active and
latent TB, and drug-resistant forms of TB, in all age groups
and in HIV-infected populations, was deemed a priority.
Diagnostic test development was to aim for at least one
simple, robust and affordable test that could be used as a
rapid and accurate diagnosis of TB at points of care (POC)
within all peripheral health systems, and a test for latent
infection capable of identifying people at the greatest risk
of progression to active TB disease.
For improved drug treatment outcomes, it was planned
that development of new drugs with a new shorter
4-month TB regimen including at least one new TB drug
would be approved by regulatory authorities for drug
sensitive TB, recommended by WHO, and available for
use globally. Other drug development targets were at
least one new drug for the treatment of multidrug-
resistant TB (MDR-TB) available; a 9-month regimen for
treatment of MDR-TB (including at least one new drug)
in a Phase III trial; and a safer, shorter duration, higher-
efficacy regimen available for treatment of latent TB
infection.
For new TB vaccine development, the Global Plan aimed
for four new TB vaccine candidates to have entered Phase
III clinical trials for safety and efficacy; with assays to
determine biomarkers and correlates of immunity incor-
porated into clinical trials; and sufficient manufacturing
capacity and licensing agreements in place to ensure an
ample, affordable supply of new TB vaccines.
It has been a decade since the formation of the STOP TB
Partnership, and the time is ripe to take stock of progress
and reflect on the future. Since the launch of the Global
Plan to Stop TB in WHO, (2006), an increased, but not
optimal, investment for development of new TB diagnos-
tics, biomarkers, drugs and vaccines has led to several
promising new technologies and a number of high-quality
product potential candidates (Ma et al. 2010; Wallis et al.
2010; Kaufmann et al. 2010). A renaissance of research
activities and funder investment has led to development of
a pipeline of new TB diagnostics, drugs and vaccines.
Biomarker discovery has lagged behind.
Progress in development of new TB diagnostics
A number of important new developments in TB diagnos-
tics give hope for the future of TB control (Table 1) (Wallis
et al. 2010; WHO ⁄TDR, 2008; McNerney & Daley 2011;
World Health Organization, 2009a,b). The WHO Stop
TB Partnership’s New Diagnostics Working Group and
Foundation for Innovative New Diagnostics (FIND) has
classified tools for the diagnosis of active TB as the
following: ‘WHO-endorsed’ tools in ‘late-stage develop-
ment or evaluation’ and tools in ‘early-stage development’.
New WHO-endorsed tools include molecular line probe
assays (LPAs) MDR-TB diagnosis and a rapid detection
and speciation assay Capilia TB-Neo to assist culture.
Light-emitting diode (LED) fluorescence microscopy was
recommended to WHO by the Strategic and Technical
Advisory Group for Tuberculosis (STAG-TB) in 2009 as an
alternative to conventional microscopy. Three non-com-
mercial culture and drug susceptibility methods were
recommended by STAG-TB in 2010: the colorimetric
redox indicator method, the microscopic observation drug
susceptibility assay (MODS) and the nitrate reductase
assay. Other diagnostic tools (WHO ⁄TDR, 2008;
McNerney & Daley 2011) in development include a
breathalyser screening test (Jassal et al. 2010), isothermal
nucleic acid amplification assays (Aryan et al. 2010),
phage-based tests for rapid diagnosis of MDR-TB
(Yzquierdo et al. 2009), MPT64 skin patch (TB Patch
backgrounder. Sequella, Inc. Rockville, MD. Transrenal
urinary DNA detection and LAM antigen detection (Peter
et al. 2010), among others (McNerney & Daley 2011).
Not all new TB diagnostic tests have proved advanta-
geous, and in 2010, STAG TB made negative recommen-
dations for two recent technologies: commercial serological
tests and interferon gamma release assays (IGRAs), to
discourage their use in TB endemic countries (WHO
Report, 2010). A similar comment has recently been made
by the ECDC (http://ecdc.europa.eu/en/publications/
Publications/1103_GUI_IGRA.pdf).
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MTB ⁄RIF assay for TB diagnosis – a significant new
development?
The development of a commercially available tool, the
Xpert MTB ⁄RIF assay (Cepheid, California, USA),
(Helb et al. 2010; Watts, 2010; Boehme et al. 2010) has
been deemed a significant development for TB diagnostics
by the WHO (MTB ⁄RIF assay recommendations: http://
www.who.int/tb/laboratory/roadmap_xpert_mtb-rif.pdf).
The performance of Xpert MTB ⁄RIF automated real-time
PCR molecular test for simultaneously identifying
M. tuberculosis DNA, and RIF, with fully integrated
sample processing, was performed in 1730 patients with
suspected drug-sensitive or multidrug-resistant pulmonary
TB in a multicountry study (Peru, Azerbaijan, South
Africa and India) (Boehme et al. 2010). Among culture-
positive patients, a single, direct MTB ⁄RIF test identified
551 of 561 patients with smear-positive TB (98.2%) and
124 of 171 with smear-negative TB (72.5%). The test was
specific in 604 of 609 patients without TB (99.2%).
Among patients with smear-negative, culture-positive test
results, the addition of a second MTB ⁄RIF assay
increased sensitivity by 12.6% and the addition of a third
by 5.1% to a total of 90.2%. Compared to phenotypic
drug susceptibility testing, MTB ⁄RIF testing correctly
identified 200 of 205 patients (97.6%) with rifampicin-
resistant bacteria and 504 of 514 (98.1%) with rifampi-
cin-sensitive bacteria. Sequencing resolved all but two
cases in favour of the MTB ⁄RIF assay. Based on this and
supporting as yet unpublished data, MTB ⁄RIF assay has
recently been endorsed by WHO Stop TB Partnership for
use and adoption at POC globally (MTB ⁄RIF assay
recommendations: http://www.who.int/tb/laboratory/
roadmap_xpert_mtb-rif.pdf). The assay sensitivity is
higher than that of smear microscopy (10 000 cfu ⁄ml)
and close to that of liquid culture (10–100 cfu ⁄ml) (Helb
Table 1 Summary of WHO tuberculosis new diagnostic recommendations (adapted from references Wallis et al. 2010; World Health
Organization, 2009a,b)
New diagnostic test Year Recommendations
Liquid media for
culture and DST
2007 WHO recommends, as a stepwise approach:
The use of liquid medium for culture and DST in middle- and low-income countries.






2008 The guiding principles for use of line probe assays:
Adoption of line probe assays for rapid detection of multidrug-resistant tuberculosis (MDR-TB)
should be decided by Ministries of Health within the context of country plans for appropriate
management of MDR-TB patients, including the development of country-specific screening
algorithms and timely access to quality-assured second-line anti-TB drugs.
LED-microscopy 2009 Conventional fluorescence microscopy to be replaced by LED microscopy in all settings and that







2009 WHO recommends that of selected non-commercial culture and DST methods be used as an
interim solution in resource-constrained settings, in reference laboratories or those with sufficient
culture capacity, whilst capacity for genotypic and ⁄ or automated liquid culture and DST are
built.
Microscopically observed drug susceptibility (MODS
The nitrate reductase assay (NRA) for screening of patients suspected of having MDR-TB
Colorimetric redox indicator (CRI) methods, as indirect tests on Mycobacterium tuberculosis
isolates from patients suspected of having MDR-TB
MTB ⁄RIF assay 2010 WHO Expert Group and STAG-TB recommendations
Xpert MTB ⁄RIF should be used as the initial diagnostic test in individuals suspected of MDR-
TB or HIV-associated TB
Xpert MTB ⁄RIF may be used as a follow-on test to microscopy in settings where MDR and ⁄ or
HIV is of lesser concern, especially in smear-negative specimens
Xpert MTB ⁄RIF is suitable for use at district and sub-district level, outside of conventional
laboratory settings, compared to conventional culture and DST which are suitable only at
national or regional level in reference laboratory settings.
Xpert MTB ⁄RIF technology does not eliminate the need for conventional microscopy culture
and DST, which are required to monitor treatment progress and to detect resistance to drugs
other than rifampicin.
MDR-TB, multidrug-resistant TB; RIF, resistance to rifampin; STAG-TB, Strategic and Technical Advisory Group for Tuberculosis.
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et al. 2010). The assay is also said to be highly specific
with no cross-reaction with non-tuberculous mycobacteria
and normal flora of the respiratory tract.
MTB ⁄RIF assay – point of care test or not is the
question?
The characteristics of Xpert MTB ⁄RIF assay meet some of
the minimum POC specifications by the STOP TBWorking
Group on New Diagnostics (Helb et al. 2010). The assay is
said to be robust, could be performed by low-skilled
technicians and detects both M. tuberculosis and rifampi-
cin resistance in sputum samples collected from adults
within 2 h, of which only a few minutes hands-on
attendance is required by the operator. The instrument
operates at a wide range of room temperatures (15–30 C)
and in humid conditions. The Xpert MTB ⁄RIF assay is said
not to be associated with a measurable infection risk and
results in a lower biohazard compared with conventional
smear microscopy. The Xpert MTB ⁄RIF assay was devel-
oped and evaluated in collaboration with the FIND, and
a reduced pricing structure has been established for
non-commercial health providers in countries where TB
is endemic.
Rate-limiting steps of the MTB ⁄RIF assay
Whilst the Xpert MTB ⁄RIF assay appears to be a long-
awaited breakthrough for TB diagnostics, the rate-limiting
steps of this new technology are that this device does not
appear to fulfil the need for a POC diagnostic test aimed
for by the STOP TB Partnership: a test that can be
implemented in the most peripheral settings in high TB
endemic areas (Van Rie et al. 2010) that often have highly
limited infrastructure and resources and are not suited for
operating and maintaining computer-driven real-time
PCR-based equipment. POC specifications that are not yet
met are reagent shelf-life of approximately 1 year
compared with the required 2 years; required annual
instrument maintenance; high cost of the machine and
cartridges; and need for continuous electrical power. Time
of the assay is also at the upper limit, and some clinics will
not be able to deliver same day treatment for those found
positive with the test. Safe disposal recycling of large
volumes of plastic cartridges remains an environmental
concern.
MTB ⁄RIF assay and rifampicin resistance
Doubts have been raised about the usefulness of the
MTB ⁄RIF assay in detection and surveillance for drug-
resistant TB (Van Rie et al. 2010; Bhanot 2011; Zbinden
et al. 2011; Mohapatra 2011). There are also issues
about the interpretation of a positive rifampicin resistance
result and its usefulness for management in settings that
do not have capacity for DOTS-Plus and treatment of
MDR-TB (Zbinden et al. 2011; Mohapatra 2011). False-
positive test for rifampicin resistance (Bhanot 2011;
Zbinden et al. 2011) is being reported, which in clinical
practice may be deleterious to patients. Other concerns
have been expressed about the quality assurance for
rifampicin resistance for the assay in resource-poor
countries (Boehme et al. 2010).
Population groups unlikely to benefit fromMTB ⁄RIF assay
Tools that predict disease progression, screen for multidrug
and extensive drug resistance (MDR and XDR respec-
tively), extrapulmonary TB, sputum-negative TB and
paediatric TB are still lacking and need further investment
and research. Up to 30% of cases of TB cases occur in
children who mostly do not produce sputum and where the
diagnosis of TB is challenging (Hesseling et al. 2011).
Furthermore, the usefulness of the MTB ⁄RIF assay in
people living with HIV ⁄AIDS, who are either unable to
produce sputum specimens, or are likely to produce
paucibacillary specimens, needs evaluation. As a result,
these patient populations will continue to have access
to diagnostics of suboptimal performance, and
significant number of active TB cases will remain
undiagnosed.
Practicalities of implementation at POC
Importantly, discovery of new diagnostic tools like the
MTB ⁄RIF assay does not necessarily ensure their adoption
and use in high TB endemic areas. Translation of new tools
to POC requires a better understanding of barriers to
implementation. For example, two decades, a large
investment has gone into developing appropriate low-cost
CD4 count testing for patients on antiretroviral therapy
(ART) in Africa (Janossy 2008). Despite these attempts at
developing a point of care tool, CD4 counting remains
restricted to centralised services and not POC (Maclennan
et al. 2008). Many African countries have upgraded their
laboratory services with these flow cytometers. Many of
these machines have become redundant within a few years
of usage because of unavailability of regular servicing,
quality control and sustained funding. Lessons must be
learnt here. The true programmatic impact of the imple-
mentation of MTB ⁄RIF assay will only be feasible through
political commitment and substantial collateral funder
investment. Several ‘point of care’ studies evaluating the
MTB ⁄RIF assay in a variety of clinical situations in
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different geographical regions are underway. The need to
standardise the designs of new studies is crucial so that
valid comparisons can be made. The final verdict on the
practical application of this MTB ⁄RIF assay at POC is
awaited.
Progress in the development of new TB Drugs
There have also been important advances in new TB drug
development (Ma et al. 2010; Lienhardt et al. 2010)
(Table 2). Despite the demonstrated efficacy in clinical trial
of the standard 6-month chemotherapy of active drug-
susceptible TB, it requires direct supervision to ensure
adequate treatment adherence and prevention of drug
resistance (Lienhardt et al. 2010). In addition, TB remains
a leading cause of death in HIV-infected people in the
developing countries, and treatment of TB in HIV-infected
populations is difficult, because of potentially severe drug–
drug interactions between rifampicin and some antiretro-
viral drugs (Ma et al. 2010; Lienhardt et al. 2010). Drugs
that are active against drug-resistant forms of TB are less
potent, more toxic and need to be taken for at least
18 months. Shorter and simpler regimens that are safe,
well tolerated, effective against drug-susceptible and drug-
resistant TB, appropriate for joint treatment with ART,
children-friendly and amenable to routine programmatic
conditions are all needed urgently. Robust patient support
systems are required to ensure high levels of adherence to
treatment are achieved. The Global Plan to STOP TB
(WHO, 2006) calls for a more concerted action to develop
and introduce new drugs, preferably with novel mecha-
nisms of action.
New TB drug pipeline
Significant progress has been made over the last 5 years,
and there is a coordinated portfolio of promising new
compounds on the horizon (Table 2) (Ma et al. 2010;
Lienhardt et al. 2010). There are at present eleven new
drugs in clinical development, which will likely lead to
two newly approved drugs by 2015 (Ma et al. 2010;
Lienhardt et al. 2010). Of these, three are in Phase I
(safety) trials, six are in Phase II (early bactericidal activity
and sputum conversion) trials, and two are in Phase III
(efficacy) trials. At least five TB drug candidates are
presently in pre-clinical development, and at least 23
additional candidates to identify new compounds are in
the discovery phases.
Table 2 Current global TB drug research and development portfolio based on information compiled by the Stop TB Partnership. Working
Group on New Drugs (from references Ma et al. 2010; Lienhardt et al. 2010)
TB, tuberculosis.
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Fluoroquinolones
Gatifloxacin and moxifloxacin, recently developed fluor-
oquinolones, have shown better in vitro activity against
M. tuberculosis than have ofloxacin and ciprofloxacin.
On the basis of results from a mouse model of
tuberculosis infection, moxifloxacin-containing regimens
have the potential to shorten treatment of drug-suscep-
tible TB from the present 6 months to 4 months. Rates
of 2-month sputum culture conversion seemed better in
Phase 2 trials in which gatifloxacin or moxifloxacin was
substituted for ethambutol or isoniazid in the control
regimen. Phase 3 trials are in progress for investigation
of whether treatment of drug-susceptible TB can be
shortened to 4 months by substitution of gatifloxacin
for ethambutol or moxifloxacin for ethambutol or
isoniazid.
Other classes of drugs
Two nitroimidazoles are in clinical development, PA-824
and OPC-67683. OPC-67683 Phase 1 is being assessed in a
Phase 2 trial for the treatment of MDR-TB. A Phase II,
stage 1 double-blind, placebo-controlled study with
TMC207 in patients with MDR tuberculosis has been
performed (Diacon et al. 2009). Clinical studies are in
progress to assess the effects of high doses of rifapentine
once or twice per week given with moxifloxacin and daily
rifapentine in the first-line regimen to shorten treatment.
The ethylenediamine, SQ-109, is a derivative of ethambu-
tol and interacts synergistically with isoniazid and rifam-
picin. Phase 1 studies of SQ109 are complete, and Phase 2
studies are to start soon (http://www.edctp.org/uploads/
tx_viprojects/Project_Profile_IP_TB_32011_Michael_
Hoelscher.pdf Accessed February 28th 2011). No new
drug or treatment regimen is yet available for treatment of
latent TB infection.
Better planning for new TB drug evaluation is required
Despite this progress, the drug pipeline for TB is still
insufficient for global needs. The Global Alliance for TB
Drug Development initially estimated that one new TB
drug would be introduced into clinical practice by 2010.
This has not yet happened. One of the main challenges in
TB drug development is the lack of global clinical trial
capacity to conduct late-stage controlled trials necessary
for product registration. Multiple trial sites are required to
assess the safety and efficacy of new compounds and
regimens and to take into account regional variations.
Product registration trials for FDA approval are burden-
some, and protracted affairs and results of evaluation of
new drugs will be slow in coming. An expansion in the
numbers of sites TB endemic countries capable of con-
ducting trials compliant with international good clinical
practice (GCP) and good clinical laboratory practice
(GCLP) standards is required. The European Developing
Countries Clinical Trials Partnerships (EDCTP) is leading
the way for African capacity development (Zumla et al.
2010). Other funding agencies need to follow suit, and the
Global alliance needs to include capacity development into
its investment portfolio.
Progress in development of new TB vaccines
New TB vaccines are urgently needed if the goal of
substantially reducing the incidence of TB by 2050 is to
be reached. According to recent modelling studies, the
introduction of new effective TB vaccines and vaccina-
tion strategies will make a crucial contribution to achieve
the STOP TB Partnership’s goal to reduce the global
incidence of TB disease to less than one case per million
population by 2050. Research and Development of new
vaccines for protection against TB is gaining momentum
as reviewed by Kaufmann et al. (2010). The past 5 years
has increased the pipeline of TB vaccine candidates
(Table 3). Over the past decade, 12 vaccine candidates
have left the laboratory stage and entered clinical
trials. These vaccines are either aimed at replacing the
present vaccine, Bacille Calmette-Gue´rin (BCG), or at
enhancing immunity induced by BCG. However, these
pre-exposure candidates are designed for the prevention
of disease and will therefore neither eradicate the
pathogen nor prevent stable infection.
The main target for vaccine development in the Global
Plan to Stop TB 2006–2015 was that two vaccines would
be in proof-of-concept trials by 2010 and that one new and
safe vaccine would be available by 2015. As of 2009, TB
vaccine candidates had entered clinical trials (Kaufmann
et al. 2010) (Table 3). Of these, nine are still being tested:
five are in Phase I (safety) clinical trials, two are in Phase II
trials, and two are in Phase IIb ‘proof-of-concept’ trials.
One vaccine has produced estimates of safety and effec-
tiveness in a targeted HIV-infected population. At least six
TB vaccine candidates are in preclinical development, and
at least 21 additional next-generation candidates are in the
vaccine discovery phase. Research into the development of
new TB vaccine candidates is also underway to evaluate
new delivery platforms that would be affordable and
suitable for resource-limited settings, including needle-free
delivery. There remains an urgent need for modern, safe
and effective vaccines that prevent all forms of TB, in all
age groups, in all geographical areas and among people
living with HIV.
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Progress in development of new TB biomarkers
In contrast to advances made in the development of TB
diagnostics, drugs and vaccines, progress in discovery of
new TB biomarkers for monitoring TB disease activity,
relapse and cure has been slow. Recent advances in
technology now allow for multiple markers to be studied
(Doherty & Robert 2009; Kaufmann & Parida 2008;
Jacobsen et al. 2007; Kunnath-Velayudhan et al. 2010;
Maertzdorf et al. 2011; Banchereau et al. 2010). In an
attempt to identify new biomarkers, several ambitious
projects are now using highly multiplexed assays to
compare gene expression between patients with TB,
healthy persons with latent TB and healthy controls with
no exposure to M. tuberculosis. It is now thought that
multiple biomarkers, when combined, may perform sub-
stantially better than any single marker, and a small
number of studies suggest that specificity and higher
predictive values can be achieved by measuring multiple
parameters by proteomics, transcriptomics and metabolo-
mics. Most of the studies aim to visualise new marker
patterns, identified by these platforms, by comparing
clinically well-defined cohorts. A challenge will certainly be
to define the correlates of immune protection in individuals
with latent TB and in those individuals that fail to
effectively eradicate or contain M. tuberculosis. The
development of new ‘marker test-beds’ may aid to differ-
entiate TB from other infectious and inflammatory condi-
tions. These emerging technologies may further shed light
on pathogenesis and may lead to discovery of potential
new biomarkers and diagnostics for monitoring drug
efficacy in clinical trials.
A recent study of South African patients (Banchereau
et al. 2010) with active and latent TB infection LTBI
identified a whole blood 393 transcript signature for
active TB in intermediate and high-burden settings,
correlating with radiological extent of disease and revert-
ing to that of healthy controls after treatment. A subset of
patients with latent TB had signatures similar to those in
patients with active TB. It has become clear that multi-
parameter assays generate associations, which may not be
totally spurious, but which are specific to the precise
population under test and may not necessarily be broadly
applicable. It is important and that tests must be devel-
oped and adapted for easy use at POC in resource-poor
settings.
Historical reflections on TB control
The persistence of TB as a major killer disease today
despite effective treatment being available informs us of
the multifactorial aetiology of TB. TB will continue to
outwit the human race until we tackle the social,
economic, political conditions that allow a treatable
disease to thrive. During the 19th century, the white
plague, as TB was named (because of the loss of skin
colour seen in London patients with TB), continued to
ravage Europe where up to 25% of deaths were caused by
this disease (Zumla 2011). The death toll from TB began
to fall in Europe at the start of the 20th century, as living
standards (better housing, nutrition and economic status)
improved; subsequent TB control was achieved following
the introduction in the 1950s of antituberculosis drugs,
mass screening programmes and BCG vaccination.
Investments in the development and implementation of
new diagnostics, drugs, vaccines and biomarkers should
be paralleled by efforts to improve living standards of the
poor peoples of this world.
Table 3 New TB vaccines in various stages of clinical trials [from Kaufmann et al. (2010)]
Name Description Developmental stage
MVA85A Attenuated strain of vaccinia expressing Ag85A Phase I completed and Phase II
ongoing. Phase IIb in infants commenced.
rBCG30 BCG overexpressing Ag85B Phase I completed.
Aeras 402 Non-replicating Ad35 expressing Ag85A, Ag85B and TB10.4 Phases I and II ongoing.
AdAg85A Non-replicating Ad5 expressing Ag85A Phase I
M72 Recombinant fusion (Mtb39 and Mtb32) in AS02A and
AS01B adjuvants
Phases I and II completed;
additional trials ongoing.
Hybrid-1 Recombinant fusion of Ag85B-ESAT-6 in IC31 adjuvant Phase I completed.
SSI HyVac-4
(Aeras 404)
Recombinant fusion of Ag85B-TB10.4 in IC31 adjuvant Phase I commenced.
rBCGDUreC:Hly BCG with an endosome escape mechanism Phase I commenced.
RUTI Detoxified Mycobacterium tuberculosis in liposomes Phase 1 completed.
M. vaccae Inactivated M. vaccae Phase III completed.
TB, tuberculosis.
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Conclusions
The past decade has seen a renaissance of scientific
activities and funder investment into development of new
TB drugs, diagnostics, biomarkers and vaccines. A prom-
ising and important portfolio of new TB diagnostics, new
TB drugs and vaccines has been endorsed by the STOP TB
Partnership. The increasing numbers of Phase 2 and 3
drug, vaccine and diagnostic clinical trials in high-TB
endemic areas reflect good progress towards attaining
STOP TB targets. The challenge now is to complete
development and validation of these in high-TB and high-
TB ⁄HIV burden countries and then translate them to
clinical practice at peripheral points of health care.
Achievement of these goals will depend largely on political
will and serious investment by funders and developing
country governments into improving deliver of better
health services and living conditions for their people and
sustaining them long term.
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